Clinical Trials Sponsored by Neuroscouting, L.L.C.

Total 581 results

Johnson & Johnson Pharmaceutical Research & Development...

Completed

The Effect of Epoetin Alfa on the Anemia of Patients With Multiple Myeloma

Multiple Myeloma | Anemia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Facilitating the Presurgical Collection of Blood to be Used for Self-donation During Surgery on the Spine, Hip, or Knee.

Anemia | Orthopedic Procedures | Blood Transfusions, Autologous
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Determine the Safety and Effectiveness of Epoetin Alfa in Facilitating Self-donation of Blood Before Surgery in Patients Who Are Not Anemic and Who Will be Undergoing Orthopedic or Heart and Blood Vessel Surgery

Blood Transfusion | Orthopedic Surgery | Orthopedic Procedures | Cardiovascular Surgical Procedure | Blood Transfusion, Autologous
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Phase 2 Study of Farnesyl Transferase Inhibitor (R115777, Tipifarnib) in Patients With Refractory or Relapsed Acute Myeloid Leukemia.

Leukemia, Nonlymphocytic, Acute
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

An Efficacy and Safety Study of Cisapride in Patients With Chronic Gastroparesis After Failure of Other Treatment Options

Gastroparesis
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

A Study of Cisapride in Premature Infants With Feeding Problems

Infant, Premature | Infant, Newborn
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

A Study of Cisapride in Patients With Symptomatic Gastro-Oesophageal Reflux Disease

Gastroesophageal Reflux
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder

Bipolar Disorder | Manic Episode
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Manic Episodes Associated With Bipolar I Disorder

Bipolar Disorders | Manic Episode
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess Safety and Tolerabiltiy Associated With a Switch From Oral Antipsychotic Medications to Long-acting Injectable Risperidone in Patients With Schizophrenia.

Psychotic Disorders | Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Safety and Efficacy of Long-term Correction of Anemia With Epoetin Alfa in Early Hemodialysis Patients

Anemia | Kidney Failure, Chronic
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Impact of Maintaining Hemoglobin Levels Using Epoetin Alfa in Patients With Metastatic Breast Cancer Receiving Chemotherapy

Quality of Life | Breast Neoplasms | Anemia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A First-in-Human Study of JNJ-28431754 in Healthy Male Volunteers

Healthy
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Clinical Study to Investigate the Effect on Pain Relief of a Single Dose of JNJ-39439335 in Patients With Chronic Osteoarthritis Pain of the Knee

Osteoarthritis, Knee
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Intramuscular Injections of Paliperidone Palmitate in the Arm or Buttock of Subjects With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of Paliperidone Blood Concentrations in Patients With Schizophrenia After Administration of Paliperidone Palmitate

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate Pharmacokinetics, Safety and Tolerability After a Single Dose Administration of JNJ-31001074 in Pediatric Patients (12-17 Years) With Attention Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder | Attention Deficit Disorders With Hyperactivity
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of JNJ-38431055 in Volunteers With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients (MAGELLAN)

Venous Thromboembolism

Belgium, France, Norway, Spain, China, Taiwan, United States, Switzerland, Colombia, Canada, Estonia, New Zealand, Finland, Italy, Portugal, Japan, Singapore, Germany, Greece, Australia, Sweden, Austria, Chile, Slovakia, United Kingdom, M... and more
Johnson & Johnson Pharmaceutical Research & Development...
PharmaMar

Completed

An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS)

Sarcoma

United States, France, United Kingdom, Spain, Germany
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study

Venous Thromboembolism

United Kingdom, Belgium, France, Israel, Italy, Spain, China, Hong Kong, Korea, Republic of, New Zealand, Poland, India, United States, Hungary, Singapore, Canada, Australia, Netherlands, Austria, Switzerland, Taiwan, Brazil, Denmark, German... and more
Johnson & Johnson Pharmaceutical Research & Development...
PharmaMar

Completed

An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer

Ovarian Cancer

United States, France, Poland, United Kingdom, China, Belgium, Germany, Hong Kong, Taiwan, Spain, Canada, Netherlands, Sweden, Korea, Republic of, Singapore, Russian Federation, Argentina, Brazil, Chile, Australia
Johnson & Johnson Pharmaceutical Research & Development...
Bayer

Completed

An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation

Stroke | Embolism | Atrial Fibrillation

United States, Australia, France, Poland, Ukraine, United Kingdom, China, Belgium, Germany, Taiwan, Spain, Argentina, Colombia, Israel, Mexico, Bulgaria, India, Malaysia, Romania, Russian Federation, South Africa, Turkey, Korea, Republic... and more
Johnson & Johnson Pharmaceutical Research & Development...
PharmaMar

Completed

An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer

Breast Neoplasms

United States, France, Israel, Poland
Carolina Musculoskeletal Institute
Baylor University; Pamlab, L.L.C.

Completed

Restoration of Cutaneous Sensorum in Patients With Diabetic Peripheral Neuropathy (DPN) Via Metanx®

Diabetic Peripheral Neuropathy

United States
Johnson & Johnson Pharmaceutical Research & Development...
PharmaMar

Completed

A Study of ET-743 (Trabectedin) in Patients With Advanced Breast Cancer

Neoplasms | Skin Diseases | Neoplasms by Site | Breast Neoplasms | Breast Diseases
Rheumazentrum Ruhrgebiet
Centocor Ortho Biotech Services, L.L.C.

Unknown

European Ankylosing Spondylitis Infliximab Cohort (EASIC) Follow up Registration Study (EASIC registry)

Ankylosing Spondylitis

Belgium, Germany, Finland, France, Netherlands, United Kingdom
Centocor Ortho Biotech Services, L.L.C.
Schering-Plough

Completed

Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONIC

Crohn Disease

United States, France, United Kingdom, Germany, Spain, Belgium, Israel, Greece, Canada, Netherlands, Austria, Norway, Denmark, Sweden, Portugal
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 Inducer

Venous Thrombosis | Deep Vein Thrombosis

Italy, Austria, Brazil, Hungary, Netherlands, South Africa, Israel, Australia, Germany
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis

Venous Thromboembolism

France, Italy, Czech Republic, Canada, Netherlands, Australia, United States, Poland, South Africa, Sweden, Israel, Denmark, Brazil
Johnson & Johnson Pharmaceutical Research & Development...
PharmaMar

Completed

A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer

Leiomyosarcoma | Liposarcoma

United States, France, Spain, Germany, Australia, Canada, Russian Federation, Belgium
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study

Pulmonary Embolism

United Kingdom, Belgium, France, Israel, Italy, Spain, China, Hong Kong, Switzerland, United States, New Zealand, Poland, India, Hungary, Singapore, Canada, Australia, Netherlands, Austria, Estonia, Thailand, Brazil, Germany, Korea, Republic... and more
Johnson & Johnson Pharmaceutical Research & Development...
PharmaMar

Completed

A Study of Trabectedin in Patients With Advanced Ovarian Cancer

Neoplasms | Neoplasms by Site | Ovarian Diseases | Adnexal Diseases | Endocrine Gland Neoplasms | Ovarian Neoplasms | Genital Diseases, Female
Johnson & Johnson Pharmaceutical Research & Development...
PharmaMar

Completed

Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma

Uterine Neoplasms | Endometrial Neoplasms | Genital Neoplasms, Female Urogenital Neoplasms

United States, Canada, Russian Federation, Netherlands
Johnson & Johnson Pharmaceutical Research & Development...
Shire

Completed

Safety and Efficacy of High Dose, Rapid Titration Galantamine in Patients With Alzheimer's Disease

Dementia | Alzheimer's Disease
Icagen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Terminated

A Study Evaluating the Long-Term Safety of ICA-17043 in Sickle Cell Disease Patients With or Without Hydroxyurea Therapy

Sickle Cell Disease | Sickle Cell Anemia

United States
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Bioequivalence Study in Healthy Subjects, 2*5 mg Tablets Rivaroxaban Versus 1*10 mg Tablet Rivaroxaban

Therapeutic Equivalency

Germany
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Switching Study From Warfarin to Rivaroxaban

Venous Thrombosis

Germany
Johnson & Johnson Pharmaceutical Research & Development...
Bayer

Completed

An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome

Myocardial Infarction | Myocardial Ischemia | Acute Coronary Syndrome | Unstable Angina

United States, France, Poland, Ukraine, United Kingdom, China, Belgium, Germany, Spain, Argentina, Chile, Colombia, Israel, Mexico, Portugal, Bulgaria, India, Malaysia, Romania, Russian Federation, Serbia, Turkey, Korea, Republic of, ... and more
Johnson & Johnson Pharmaceutical Research & Development...
PharmaMar

Completed

Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma

Liposarcoma,Myxoid

France, United States, Germany
Johnson & Johnson Pharmaceutical Research & Development...
PharmaMar

Completed

A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram

Solid Tumor

France, United States, Belgium, India, Korea, Republic of, Russian Federation, Spain
Johnson & Johnson Pharmaceutical Research & Development...
PharmaMar

Completed

A Phase 2 Study of Trabectedin (Yondelis) in Adult Male Participants With Advanced Prostate Cancer

Prostate Cancer

United States
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study

Venous Thrombosis

United Kingdom, Belgium, France, Israel, Italy, Spain, China, Hong Kong, Korea, Republic of, United States, New Zealand, Poland, India, Hungary, Singapore, Canada, Australia, Netherlands, Austria, Switzerland, Brazil, Denmark, Germany, Norw... and more
Centocor Ortho Biotech Services, L.L.C.
Schering-Plough

Completed

RESTART C0168Z05 Rheumatoid Arthritis Study

Rheumatoid Arthritis

United States, United Kingdom, Spain, Israel, Finland, Canada, France, Austria, Germany, Netherlands
Johnson & Johnson Pharmaceutical Research & Development...
Bayer

Completed

Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Patients With Acute Coronary Syndromes (The ATLAS ACS TIMI 46 Trial)

Acute Coronary Syndrome
Mayo Clinic
Centocor Ortho Biotech Services, L.L.C.

Completed

Intestinal Wall Remodeling (Infliximab Therapy) in Crohn's Disease Patients Undergoing Serial Computed Tomography (CT) Enterography

Crohn's Disease

United States
Fondren Orthopedic Group L.L.P.

Not yet recruiting

Impact of Glenosphere Size on Range of Motion in Female Patients Undergoing Reverse Shoulder Arthroplasty

Rotator Cuff Tear Arthropathy | Massive Irreparable Rotator Cuff Tear

United States
Fondren Orthopedic Group L.L.P.

Withdrawn

Pain Control With Pre-operative Cryoneurolysis Following TKA

Osteo Arthritis Knee

United States
Tangent Data
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

The Effects of JNJ-39393406 on Psychometric Performance and Residual Depressive (JNJ-DEP)

Depression

Moldova, Republic of, Romania

Clinical Trials Sponsored by Neuroscouting, L.L.C.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mexico

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations